IndustryCompany release

UCB raises 2026 guidance for second time on stronger US BIMZELX and CIMZIA sales

UCB · Thu 22 Oct 2026

The Belgian biopharma now expects low-twenties revenue growth and low- to mid-forties adjusted EBITDA growth at constant exchange rates, citing US performance of its two key products.

UCB announced on 22 October 2026 that it is upgrading its full-year 2026 guidance for the second time. The company now expects revenue growth in the low twenties and adjusted EBITDA growth in the low- to mid-forties, both measured at constant exchange rates.

For BIMZELX, UCB points to continued volume growth and more favourable net pricing in the US. For CIMZIA, it cites volume growth, more moderate 340B dynamics and improved pricing. The 340B programme is a US federal scheme requiring drug discounts for certain eligible healthcare providers.

The guidance excludes any proceeds from the sale of a priority review voucher. UCB will publish its full-year results on 25 February 2027.

The summary available to VigiEye gives no absolute revenue or EBITDA figures, no breakdown by product and no detail on the previous guidance ranges.

What it means for your team

  • Market-access teams should note that UCB attributes the upgrade partly to better US net pricing for BIMZELX and CIMZIA, alongside volume growth.
  • The reference to more moderate 340B dynamics shows that US discount-programme effects remain a visible factor in company net-price performance.
  • Detailed figures and product-level data are expected with the full-year results on 25 February 2027.

Company's press release: UCB ↗

Article written by VigiEye from the official source (UCB). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →